Genomics and Cardiovascular Drug Development

Journal of the American College of Cardiology

Volumn 53, Issue 13, 2009, Pages 1089-1100

  Plump, Andrew S ^a   Lum, Pek Yee ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ROSETTA INPHARMATICS   (United States)

Author keywords

biomarkers; cardiovascular disease; genomics; systems biology; target validation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN 2B INHIBITOR; GLYCOPROTEIN 3A INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; LIDOCAINE; LOSARTAN; NESIRITIDE; NICOTINIC ACID; PHENYTOIN; PRAZOSIN; PROPRANOLOL; QUINIDINE; RENIN INHIBITOR; TERAZOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL; WARFARIN;

ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE MARKER; DRUG RESEARCH; DRUG TARGETING; GENOMICS; GENOTYPE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MEDICAL INFORMATICS; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; FORECASTING; GENOMICS; HUMANS; MICE;

EID: 62549162170     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.11.050     Document Type: Review

References (99)

1. Morbidity & Mortality Weekly Report. Trends in Ischemic Heart Disease Death Rates for Blacks and Whites-United States, 1981-1995 (1998). http://www.cdc.gov/mmwr/preview/mmwrhtml/00055605.htm Accessed October 2008
2. Cardiovascular Disease Statistics, AHA (2008). http://www.americanheart.org/presenter.jhtml?identifier=4478 Accessed October 2008
3. WHO Cardiovascular Diseases (2007). http://www.who.int/mediacentre/factsheets/fs317/en/index.html Accessed October 2008
4. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 3 (2004) 711-715
5. Zycher B., DiMasi J.A., and Milne C.P. The Truth About Drug Innovation: Thirty-Five Summary Case Histories on Private Sector Contributions to Pharmaceutical Science. Medical Progress Report (2008), Manhattan Institute, New York, NY
6. In: Gilman A.G., Goodman L.S., Rall T.W., and Murad F. (Eds). The Pharmacological Basis of Therapeutics (1985), Macmillan, New York, NY
7. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 22 (2003) 151-185
8. Scriabine A. Challenges for cardiovascular drug research. Cardiovasc Drug Rev 259 (2007) 205-220
9. Kathiresan S., Melander O., Guiducci C., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40 (2008) 189-197
10. Willer C.J., Sanna S., Jackson A.U., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40 (2008) 161-169
11. Fahmi S., Yang C., Esmail S., Hobbs H.H., and Cohen J.C. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum Mol Genet 17 (2008) 2101-2107
12. Romeo S., Pennacchio L.A., Fu Y., et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 39 (2007) 513-516
13. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
14. Barlic J., and Murphy P.M. Chemokine regulation of atherosclerosis. J Leukoc Biol 82 (2007) 226-236
15. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
16. Schadt E.E., Lamb J., Yang X., et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37 (2005) 710-717
17. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
18. Iakoubova O.A., Sabatine M.S., Rowland C.M., et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol 51 (2008) 449-455
19. Iakoubova O.A., Tong C.H., Rowland C.M., et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol 51 (2008) 435-443
20. Zadelaar S., Kleemann R., Verschuren L., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27 (2007) 1706-1721
21. Reardon C.A., and Getz G.S. Mouse models of atherosclerosis. Curr Opin Lipidol 12 (2001) 167-173
22. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
23. Plump A.S., Smith J.D., Hayek T., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
24. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92 (1993) 883-893
25. Reddick R.L., Zhang S.H., and Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14 (1994) 141-147
26. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
27. Heeneman S., Lutgens E., Schapira K.B., Daemen M.J., and Biessen E.A. Control of atherosclerotic plaque vulnerability: insights from transgenic mice. Front Biosci 13 (2008) 6289-6313
28. Johnson J.L., and Jackson C.L. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 154 (2001) 399-406
29. Calara F., Silvestre M., Casanada F., Yuan N., Napoli C., and Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 195 (2001) 257-263
30. Plump A. New mouse models of lipoprotein disorders and atherosclerosis. In: Fuster V., Topol E., and Nabel E. (Eds). Atherosclerosis and Coronary Artery Disease. 2nd edition (2005), Lippincott-Raven, Baltimore, MD 355-374
31. AIM HIGH: Niacin Plus Statin to Prevent Vascular Events (2008). http://clinicaltrials.gov/ct2/show/NCT00120289?term=aim+high&rank=1 Accessed October 2008
32. HPS2 THRIVE: A Randomized Trial of the Long-Term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant (2008). http://clinicaltrials.gov/ct2/show/NCT00461630 Accessed October 2008
33. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., and Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 92 (1995) 8264-8268
34. Gijbels M.J., van der Cammen M., van der Laan L.J., et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 143 (1999) 15-25
35. Boden W.E., and Pearson T.A. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 85 (2000) 645-650
36. Gotto Jr. A.M. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol 82 Suppl 9A (1998) 22Q-25Q
37. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 (2008) 2524-2532
38. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
39. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
40. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
41. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
42. Bodor E.T., and Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 153 Suppl 1 (2008) S68-S75
43. Wang S.S., Shi W., Wang X., et al. Mapping, genetic isolation, and characterization of genetic loci that determine resistance to atherosclerosis in C3H mice. Arterioscler Thromb Vasc Biol 27 (2007) 2671-2676
44. Paigen B., Nesbitt M.N., Mitchell D., Albee D., and LeBoeuf R.C. Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Genetics 122 (1989) 163-168
45. Paigen B., Mitchell D., Reue K., Morrow A., Lusis A.J., and LeBoeuf R.C. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci USA 84 (1987) 3763-3767
46. Paigen B., Mitchell D., Holmes P.A., and Albee D. Genetic analysis of strains C57BL/6J and BALB/cJ for Ath-1, a gene determining atherosclerosis susceptibility in mice. Biochem Genet 25 (1987) 881-892
47. Goldstein J.L., and Brown M.S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 249 (1974) 5153-5162
48. Brown M.S., and Goldstein J.L. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science 185 (1974) 61-63
49. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
50. Mani A., Radhakrishnan J., Wang H., et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315 (2007) 1278-1282
51. Garcia C.K., Wilund K., Arca M., et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292 (2001) 1394-1398
52. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., and Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2005) 161-165
53. Manolio T.A., Rodriguez L.L., Brooks L., et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet 39 (2007) 1045-1051
54. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 357 (2007) 443-453
55. Emilsson V., Thorleifsson G., Zhang B., et al. Genetics of gene expression and its effect on disease. Nature 452 (2008) 423-428
56. Churchill G.A. The genetics of gene expression. Mamm Genome 17 (2006) 465
57. Letwin N.E., Kafkafi N., Benjamini Y., et al. Combined application of behavior genetics and microarray analysis to identify regional expression themes and gene-behavior associations. J Neurosci 26 (2006) 5277-5287
58. Cheung V.G., Jen K.Y., Weber T., et al. Genetics of quantitative variation in human gene expression. Cold Spring Harbor Symp Quant Biol 68 (2003) 403-407
59. Darvasi A. Genomics: gene expression meets genetics. Nature 422 (2003) 269-270
60. Cheung V.G., and Spielman R.S. The genetics of variation in gene expression. Nat Genet 32 Suppl (2002) 522-525
61. Schadt E.E., Molony C., Chudin E., et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6 (2008) e107
62. Helgadottir A., Thorleifsson G., Manolescu A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316 (2007) 1491-1493
63. McPherson R., Pertsemlidis A., Kavaslar N., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
64. Broadbent H.M., Peden J.F., Lorkowski S., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 17 (2008) 806-814
65. Pasmant E., Laurendeau I., Heron D., Vidaud M., Vidaud D., and Bieche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67 (2007) 3963-3969
66. Chen Y., Zhu J., Lum P.Y., et al. Variations in DNA elucidate molecular networks that cause disease. Nature 452 (2008) 429-435
67. Schadt E.E., Monks S.A., Drake T.A., et al. Genetics of gene expression surveyed in maize, mouse and man. Nature 422 (2003) 297-302
68. Zhu J., Lum P.Y., Lamb J., et al. An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet Genome Res 105 (2004) 363-374
69. Zhu J., Wiener M.C., Zhang C., et al. Increasing the power to detect causal associations by combining genotypic and expression data in segregating populations. PLoS Comput Biol 3 (2007) e69
70. Ferrara C.T., Wang P., Neto E.C., et al. Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet 4 (2008) e1000034
71. Wang S.S., Schadt E.E., Wang H., et al. Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data. Circ Res 101 (2007) e11-e30
72. Oltvai Z.N., and Barabasi A.L. Systems biology. Life's complexity pyramid. Science 298 (2002) 763-764
73. Barabasi A.L. Network medicine-from obesity to the "diseasome.". N Engl J Med 357 (2007) 404-407
74. Barabasi A.L., and Bonabeau E. Scale-free networks. Sci Am 288 (2003) 60-69
75. Ashley E.A., Ferrara R., King J.Y., et al. Network analysis of human in-stent restenosis. Circulation 114 (2006) 2644-2654
76. Skogsberg J., Lundstrom J., Kovacs A., et al. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet 4 (2008) e1000036
77. King J.Y., Ferrara R., Tabibiazar R., et al. Pathway analysis of coronary atherosclerosis. Physiol Genomics 23 (2005) 103-118
78. Mehrabian M., Allayee H., Wong J., et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 91 (2002) 120-126
79. Ridker P.M. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 65 Suppl 3 (2007) S253-S259
80. CRP CHD Genetics Collaboration. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. Eur J Epidemiol 23 (2008) 531-540
81. Timpson N.J., Lawlor D.A., Harbord R.M., et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 366 (2005) 1954-1959
82. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359 (2008) 1897-1908
83. Hingorani A., and Humphries S. Nature's randomised trials. Lancet 366 (2005) 1906-1908
84. Tardif J.C., McMurray J.J., Klug E., et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 1761-1768
85. Damas J.K., Boullier A., Waehre T., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 25 (2005) 2567-2572
86. Chittenden T.W., Sherman J.A., Xiong F., et al. Transcriptional profiling in coronary artery disease: indications for novel markers of coronary collateralization. Circulation 114 (2006) 1811-1820
87. Tabibiazar R., Wagner R.A., Ashley E.A., et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics 22 (2005) 213-226
88. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117 (2007) 746-756
89. The HRP Initiative (2007). www.hrpinitiative.com Accessed October 2008
90. Sanz J., and Fayad Z.A. Imaging of atherosclerotic cardiovascular disease. Nature 451 (2008) 953-957
91. Limdi N.A., and Veenstra D.L. Warfarin pharmacogenetics. Pharmacotherapy 28 (2008) 1084-1097
92. New Labeling Information for Warfarin (Marketed as Coumadin) (2007). http://www.fda.gov/cder/drug/infopage/warfarin/default.htm Accessed October 2008
93. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359 (2008) 789-799
94. Konig J., Seithel A., Gradhand U., and Fromm M.F. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 432-443
95. Molokhia M., McKeigue P., Curcin V., and Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS ONE 3 (2008) e2522
96. Shiffman D., Chasman D.I., Zee R.Y., et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol 51 (2008) 444-448
97. UK Biobank (2006). http://www.ukbiobank.ac.uk/ Accessed October 2008
98. Pukkala E., Andersen A., Berglund G., et al. Nordic biological specimen banks as basis for studies of cancer causes and control-more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol 46 (2007) 286-307
99. Triendl R. Japan launches controversial Biobank project. Nat Med 9 (2003) 982